A framework for investigating signals in pharmaceutical regulatory quality assurance

Abstract

Pharmaceutical regulatory assurance is a pillar in the regulatory sciences that leads to t he availability of safe, effective, and quality medicinal products. A structured approach to using signals as an instructive tool of process management in regulatory sciences is an innovative, relatively unexplored concept in the evolution of pharmaceutical regulatory sciences. This research explores a gap in the identification of disruptive signals from sources within the quality management system, categorisation of identified signals, and development of signal minimisation action plans at the heart of the regulatory, scientific field. Strategic lines of inquiry in the regulatory and scientific field can be unfolded. The objective is to formulate a novel investigative framework for identified signals within regulatory sciences quality management systems. The hypothesis is that signal categorisation serves to enhance a quality management system by strengthening the regulation to safeguard the availability of quality, safe and effective medicines. Method: The study employs a retrospective analysis of internal audit reports, quality improvement, and deviation forms within a competent authority in the medicine regulatory department. The analysis focuses on identified signals associated with operational and regulatory aspects within pharmaceutical sciences. A structured framework for categorising signals is devised, drawing upon the principles Pharmacy Education 24(7) 398 - 409 Regulatory sciences and quality outlined in Module IV of the Guideline on Good Pharmacovigilance Practice, focusing on Pharmacovigilance Audits. The assessment tool incorporates definitions for terms such as "critical," "major," "minor," and "others" and thresholds to facilitate the systematic classification of signals. In this context, 'critical' denotes a foundational deficiency within regulatory pharmaceutical procedures or methodologies, leading to adverse impacts on the regulatory framework and/or constituting a severe breach of relevant regulatory standards. 'Major' signifies a notable deficiency within regulatory pharmaceutical procedures or methodologies or a fundamental fault therein that undermines the regulatory process and/or breaches applicable regulatory standards, albeit without reaching a level of severity deemed critical. 'Minor' denotes a deficiency within regulatory pharmaceutical procedures or methodologies that is not anticipated to have adverse effects on the regulatory framework. 'Other' encompasses deficiencies or inadequacies in regulatory pharmaceutical processes or practices that do not fit within the aforementioned terms. These may include less consequential deviations from regulatory requirements or minor issues that do not present substantial risks to the regulatory integrity or compliance criteria. The competent Authority in question is patient-centric, and the relation of signal categorisation to patient safety needs to be elaborated upon. Results: The analysis of the internal documentation revealed that no cases were of a critical and major nature. Predominantly, findings were categorised as minor or other. These findings hold significance in fostering a proactive approach to signal management within the regulatory framework of signals for quality assurance, contingent upon the established classification framework. These findings are anticipated to strengthen regulatory integrity and ensure adherence to established standards. Conclusion: This research has yielded the development of a structured categorisation framework tool inspired by Module IV Pharmacovigilance Audits, as outlined in the Guideline on Good Pharmacovigilance Practice. The interaction between data, communication, and governance offers a systematic approach to organising identified signals and facilitating streamlined processes in signal classification.